To study effect of Shatapushpa Shatavari laddu in peri-menopausal syndrome

An open labeled single armed clinical study of Shatapushpa Shatavari Modak in peri-menopausal syndrome.

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/018063

Enrollment

Registered

2019-03-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N958- Other specified menopausal and perimenopausal disorders

Interventions

Intervention1: Shatapushpa Shatavari Modak: Dose - 1 OD Dosage form - 1 modak Route of administration- oral Time of administration - Rasayan Kala Anupana-Goghruta Duration of therapy -2 months Contr

Eligibility

Inclusion criteria

Inclusion criteria: Women having clinical symptoms of Perimenopausal Syndrome - 1. Hot flushes 2. Heart discomfort 3. Sleep problems 4. Depressive mood 5. Irritability. 6. Anxiety 7. Physical and mental exhaustion 8. Sexual problems 9. Bladder problems 10. Vaginal dryness. 11. Joint and muscular discomfort

Exclusion criteria

Exclusion criteria: 1. Malignancy 2. Surgical menopause 3. K/C/O - Mental illness 4. K/C/O - DM 5. K/C/O - RA, Psycho-neural-endocrinal disorders etc. 6. K/C/O - Heart Failure. 7. On prolonged medication - corticosteroids, antidepressants, HRT, etc. 8. K/C/O - Hepatic disorder

Design outcomes

Primary

Measure	Time frame
To study the effect of Shatapushpa Shatavari Modak on peri-menopausal syndrome.Timepoint: 2 months	—

Secondary

Measure	Time frame
To reduce the signs and symptoms of peri-menopausal syndromeTimepoint: 2 months	—

Countries

India

Contacts

Public ContactVd Deepali Suresh Rajput

maharashtra arogya mandals

drdeepalirajput@yahoo.com9423978584

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026